Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

4 Discounted Gems to Scoop Up on Black Friday Before They Take Off

Published 11/27/2024, 02:00 PM
CROX
-
NUE
-
LHX
-
PRGO
-
  • December in election years sees an 83.3% positive return, boosting investor confidence.
  • With many stocks overpriced in the current bull market, focusing on undervalued stocks with strong market support is crucial.
  • Let’s explore some stocks to consider this holiday season.
  • Looking for more actionable trade ideas? Subscribe here for up 55% off as part of our Bird Black Friday sale!

December often brings holiday cheer to Wall Street, especially in election years. The S&P 500 has climbed in 83.3% of Decembers during such years, a striking trend that gives investors plenty of reason to stay bullish.

Even more compelling, in the last 10 instances where the S&P 500 gained 20% or more by December, the index closed the month higher 9 times, with an average gain of 2.4%.

While the market’s lofty valuations—evident in metrics like the Shiller P/E ratio—may cause concern, savvy investors can still find opportunities. The key is to apply disciplined stock selection filters to pinpoint undervalued names with strong potential.

Here are the criteria I used to identify today's picks:

  1. Undervalued stocks: Trading below their fair or fundamental value.
  2. Broad market support: A majority of analysts rate them as buys.
  3. Upside potential: Market consensus suggests a notable average target price above current levels.
  4. Dividend yield: They reward shareholders with consistent payouts.

After applying these filters, a shortlist of promising stocks emerges. Let’s dive into the names that made the cut.

1. Crocs (CROX)

Since reporting its third-quarter results, Crocs (NASDAQ:CROX) has been falling on weakness in its HEYDUDE brand.

Crocs Price Chart

But in early November an executive, Replogle, bought shares worth a total of $252,222.

It was Replogle's third purchase this year, following previous purchases of 2,000 shares each in March and August. The November purchase was the largest so far, suggesting it was taking advantage of the stock's slump.

It will publish its quarterly accounts on February 13. For the 2024 computation the forecast is for earnings growth of 2.9% and for 2025 it would be 3.3%.
Revenue and EPS

Source: InvestingPro

The company's focus on product innovation and strategic marketing initiatives that are beginning to bear fruit are positively valued.

Targeting younger audiences with the launch of a TikTok store demonstrates the company's ability to adapt and reach consumers with a lower age range. Also contributing to this is the launch of new collaborations with popular franchises such as Beetlejuice and SpongeBob SquarePants.

International expansion continues to be a pillar of growth, with solid performance in markets such as Australia, France, Germany and China.

It has 12 ratings, of which nine are buy, three are hold and none are sell.

Its shares are trading 33.5% below their fundamental value, which would be at $144.91.

The market gives it an average target price of $135.51.
Fair Value

Source: InvestingPro

2. Nucor (NUE)

Nucor Corp (NYSE:NUE) is a U.S. company based in Charlotte, North Carolina, founded in 1965 and one of the leading producers of steel in the country.

Nucor

Shares in the steel sector rallied on Donald Trump's victory on the issue of tariffs and the Federal Reserve's interest rate cuts.

The company has increased its dividend since 1973, currently yielding 1.41%. That's not too high, but it is expected to keep increasing it as it has for more than half a century.
Dividend Data

Source: InvestingPro

It will release its quarterly accounts on February 4. The 2024 numbers are not good, but for 2025 they are expected to be much better, with EPS, or earnings per share, up 9.4%.
Nucor Data

Source: InvestingPro

The company remains optimistic about its growth strategy, with significant capital expenditures aimed at expanding capacity and improving product offerings.

The company's P/E ratio of 10.61 suggests that it may be undervalued relative to its earnings, which aligns with the company's optimistic outlook on future growth opportunities.

The market gives it an average price at $172.51.
Analyst Targets

Source: InvestingPro

It was unable to break through its resistance when it touched it in early November, hence the recent cuts.

3. L3Harris Technologies (NYSE:LHX)

It is a provider of defense technology products in the maritime, land, air, space, and cyber areas. It provides services to various commercial and government agencies, such as the U.S. Navy, Department of Defense, and Army, and has a market capitalization of $47.06 million.

It will pay a dividend of $1.16 per share on December 6, and shares must be held prior to November 18 to be eligible to receive the dividend. The company's dividend yield is 1.88%. The payments are backed by more than 20 years of steady dividend growth.
Dividend History

Source: InvestingPro

It will publish its accounts for the quarter on January 23. For the full 2024 computation, revenue growth is forecast at 9.6% and for 2025 at 3.7%.
Revenue and EPS

Source: InvestingPro

The stock trades 7.7% below its faire value or fair price by fundamentals, which is at $259.17.

The market gives it an average price target at $279.14.
Fair Value

Source: InvestingPro

4. Perrigo Company (PRGO)

Perrigo Company (NYSE:PRGO) is an American manufacturer of pharmaceuticals. It is based in Ireland for tax purposes. It was founded in 1887.

Perrigo

It has a market capitalization of $3.82 billion and a forward price/earnings (P/E) ratio of 10.85 (lower than the industry average), being undervalued compared to its peers, as well as its own five-year average multiple of 14.12.

The company offers an attractive dividend yield of 3.89% and has raised dividends for 22 consecutive years. It will pay out $0.2760 per share on Dec. 17, and you must own shares by Nov. 29 to be eligible to receive it.
Data

Source: InvestingPro

On March 3 we will know its next quarterly results, expecting an increase in EPS (earnings per share) of 14.03%.
Earnings

Source: InvestingPro

Perrigo recently completed the sale of its rare disease business HRA Pharma for up to $275 million, which will help reduce debt and allow it to focus more on its core business.

Of the 4 ratings it has, 3 are buy, 1 is hold and none are sell.

It is trading 7.6% below its fair value or price for fundamentals, which would be at 30.55 dollars.

The average target price assigned by the market is $35.80.
Fair Value

Source: InvestingPro

Ever wondered how top investors consistently outperform the market? With InvestingPro, you’ll unlock access to their strategies and portfolio insights, giving you the tools to elevate your own investing game.

But that’s not all—our AI-powered analysis delivers 100+ stock recommendations every month, tailored to help you make smarter, faster decisions.

Ready to take your portfolio to the next level? Click here to start today!

Black Friday Sale - Claim Your Discount Now!

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.